Straight out of pharma bro Martin Shkreli's playbook, Marathon Pharmaceuticals has taken a muscular dystrophy drug available overseas, shepherded it through the FDA process, and now plans to sell it on the American market for $89,000 (70 times the European and Canadian price).

For that markup, the drug gets a cool new name: Emflaza.

Perhaps Shkreli, former CEO of Turing Pharmaceuticals, said it best. "Marathon. Bro. These guys invented price increases. I literally learned it from them."

Sen. Bernie Sanders and Rep. Elijah Cummings just wrote a letter to Marathon with a few pointed questions.

How to help prevent a Turing redux

Call Marathon at (866) 945-7860 to share your thoughts on the planned price of Emflaza.

Get in on the Twitter discussion with Marathon CEO Jeff Aronin at #MarathonPharmaceuticals.